



## Moderna to Present at BMO 2020 Prescriptions for Success Healthcare Conference

June 16, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 16, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stéphane Bancel, Chief Executive Officer, will participate virtually in the BMO 2020 Prescriptions for Success Healthcare Conference on June 23<sup>rd</sup> at 3:00 p.m. ET.

A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at [investors.modernatx.com](https://investors.modernatx.com). A replay of the webcast will be archived on Moderna's website for 30 days following the presentation.

### About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit [www.modernatx.com](https://www.modernatx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200616005249/en/): <https://www.businesswire.com/news/home/20200616005249/en/>

### Investors:

Lavina Talukdar  
Head of Investor Relations  
617-209-5834  
[Lavina.Talukdar@modernatx.com](mailto:Lavina.Talukdar@modernatx.com)

Source: Moderna, Inc.